BTLA, a new inhibitory B7 family receptor with a TNFR family ligand.
B and T lymphocyte attenuator (BTLA), identified as an immune inhibitory receptor recently, plays widespread roles on T and B cells. Emerging evidence has generated plentiful information on the mechanisms which BTLA mediates negative regulation in immune responses and involves in a variety of physiological and pathological processes. The exploration of the biological mechanisms and regulation of BTLA will open possibilities on novel therapeutic strategies in immune-related diseases.
Zeng
Chun
C
Transplantation Biology Research Division, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100080, China.
Wu
Tinghe
T
Zhen
Yu
Y
Xia
Xue Pei
XP
Zhao
Yong
Y
D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D008024:Ligands; D011971:Receptors, Immunologic / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology
D008024:Ligands; D011971:Receptors, Immunologic; D018124:Receptors, Tumor Necrosis Factor